Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 8/01/19 → 31/12/20 |
A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD).
- O'Brien, Terence (Primary Chief Investigator (PCI))
Project: Research